CDSCO Drug Approvals | India | Pharma | Health | Drug Approvals | 2024 | iPharmaCenter
top of page
Namasthe
Find the healthcare and drug approval news of India, China, Japan, Australia and other Asian countries
AstraZeneca Granted CDSCO Authorization for Andexanet Alfa: Antidote for Severe Bleeding Tied to FXa Inhibitors AstraZeneca announced...
South Korea Healthcare News - MoHW aims to support supply of essential medicines | iPharmaCenter
The Ministry of Health and Welfare (Minister: Cho Gyu-hong) has announced that starting from December 1, measures such as an increase in...
COVID-19 India Updates | Covaxin approved for children | Vaccines for teenagers
India started vaccination of adolescents; Bharat Biotech says Covaxin demonstrated robust efficacy and safety in people of age 2-18 years...
China released the 2022 NDRL list, Chinese pharma benefited from the list
China has released the 2021 Drug catalog, which included 2,860 drugs, out of which 1,486 drugs are Western drugs. Reuters reported a...
WHO granted EUL to Covaxin; acclaims easy storage requirement
WHO has announced that it has granted emergency use listing for Covaxin developed by Bharat Biotech. This adds another vaccine to the...
Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio
Novartis entered a strategic collaboration with BeiGene to license tislelizumab; to market in major markets outside China, including...
Bayer submitted vericiguat for market authorization in China
Bayer has announced that it has submitted an application requesting the approval of vericiguat in China for the treatment of chronic...
Bayer’s Xofigo received approval for prostate cancer in China
Bayer has announced that the Chinese National Medical Products Administration (NMPA) approved Xofigo (radium-223 dichloride) for treating...
Merck’s Keytruda received one more indication and dosage form approval in Japan
Merck has announced that it has received the approval of its anti-PD-1 therapy, Keytruda (pembrolizumab) for radically unresectable,...
bottom of page